C4 Therapeutics
CCCC
115 hedge funds and large institutions have $103M invested in C4 Therapeutics in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 23 closing their positions.
3,075% more call options, than puts
Call options by funds: $127K | Put options by funds: $4K
34% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 29
13% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 23
2% more funds holding
Funds holding: 113 → 115 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.92% less ownership
Funds ownership: 91.23% → 90.31% (-0.92%)
56% less capital invested
Capital invested by funds: $232M → $103M (-$129M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$7.31M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.08M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$1.94M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$1.45M |
| 5 |
SG Americas Securities
New York
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.02M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.01M |
| 4 |
Millennium Management
New York
|
-$878K |
| 5 |
BlackRock
New York
|
-$819K |
CCCC Hedge Fund Activity: Q1 2025 in Review
115 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2025, worth a combined $103M — down 56% from $232M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CCCC positions and 23 closed out — a net gain of 3 holders — while 39 added to existing stakes and 29 trimmed.
The largest buyer was OrbiMed, adding an estimated $7.31M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.6M sold.
- 115 institutional investors held C4 Therapeutics (CCCC) as of Q1 2025, up from 113 in Q4 2024.
- Funds reported $103M of C4 Therapeutics stock for Q1 2025, down 56% quarter-over-quarter.
- 26 funds opened new C4 Therapeutics positions in Q1 2025 and 23 closed out, a net change of +3 holders.
- The largest C4 Therapeutics buyer in Q1 2025 was OrbiMed, an estimated $7.31M added.
- The largest C4 Therapeutics seller in Q1 2025 was RA Capital Management, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2025.